# Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

> **NCT00659438** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 95 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ZD6474 (Vandetanib)
- **DRUG:** Bicalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00659438
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-11
- **Final completion:** 2011-07
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00659438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00659438, "Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00659438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*